Clinical Trials Browser

Phase 3 × INDUSTRY × pazopanib × Clear all

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06263231 2025-07-29

INVINCIBLE-3

Phase 3 Active not recruiting

Sarcoma

NCT03592472 2025-04-13

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT00720941 2025-03-30

COMPARZ

Phase 3 Completed

1,110 enrolled 27 charts

Carcinoma, Renal Cell

NCT02049905 2024-06-13

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Phase 3 Completed

433 enrolled 10 charts

Neoplasm Metastasis, Sarcoma

NCT00866697 2021-02-16

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Completed

940 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01235962 2020-11-23

PROTECT

Phase 3 Completed

1,538 enrolled 27 charts

Carcinoma, Renal Cell, Neoplasms

NCT02979899 2020-05-12

TAPPAS

Phase 3 Completed

128 enrolled 13 charts

Hemangiosarcoma

NCT01064310 2017-04-17

PISCES

Phase 3 Completed

169 enrolled 16 charts

Carcinoma, Renal Cell, Neoplasms, Patient Preference

NCT00334282 2016-02-05

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Phase 3 Completed

435 enrolled 19 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00387764 2014-01-14

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Phase 3 Completed

80 enrolled 19 charts

Carcinoma, Renal Cell

NCT00753688 2013-08-22

PALETTE

Phase 3 Completed

369 enrolled 17 charts

Sarcoma